| INTRODUC TI ON
. 4 The most common adverse drug reactions associated with Following oral administration, DMF is rapidly hydrolyzed by esterases of the small intestine to form monomethylfumarate (MMF), its main metabolite. 5 DMF/MMF is believed to elicit its antipsoriatic effects via modulation of several signaling pathways including glutathione (GSH)-mediated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibition. This initiates a downstream cellular response to oxidative stress and shifts the immune response from a proinflammatory T helper 1/T helper 17 cell profile to an anti-inflammatory Th2 profile. 1 The mechanism of action of DMF may also involve the inhibition of ribosomal S6 kinases and mitogen-and stress-activated kinases, primarily via allosteric covalent binding to a conserved cysteine residue. 6 Many drugs act as inhibitors of cytochrome P450 (CYP) enzymes in vivo and thus may affect the disposition of other coadministered drugs that are also metabolized by these enzymes. 7 Consequently, inhibition of drug-metabolizing CYP enzymes is a major cause of clinically relevant drug-drug interactions (DDIs). Repeated administration of certain drugs may also induce CYP enzymes. Induction of this type may lead to decreased efficacy of concomitant medications and may increase formation of toxic metabolites. 
P-glycoprotein (P-gp) is a multidrug resistance (MDR) adenosine tri-
phosphate-binding cassette (ABC) transporter expressed on the apical side of gut epithelia and brain endothelia that can extrude drugs from the cell via active transport and, in doing so, limit oral absorption and brain penetration, respectively. 9 Increased P-gp activity can therefore lead to drug resistance and may influence the kinetics of drug absorption. Conversely, inhibition of the transporter can increase absorption of P-gp substrates across the gastrointestinal tract and into other organs.
As a consequence of these findings, the European Medicines Agency (EMA), 10 the US Food and Drug Administration (FDA) 11 and the Japanese Ministry of Health, Labour and Welfare (JMHLW) 12 recommend that interactions with CYP enzymes and the P-gp transporter are evaluated as part of the safety assessment and subsequent product labeling of new therapies.
Although, the chemical structures and physicochemical properties of DMF and MMF suggest that they are unlikely to interact with CYP enzymes or P-gp, available data on the interactions of DMF and MMF with these proteins are currently limited. 13 The available product labels/summary of product characteristics for Fumaderm 
| MATERIAL S AND ME THODS

| Solubility and stability of DMF and MMF
| Analysis of DMF and MMF concentrations
Liquid chromatography with LC-MS/MS determinations were carried out with aliquots (25 μL for DMF; appropriate volume for MMF)
added to 96-well plates before and after centrifugation (Table S1 ).
For DMF, an 8-point internal standard curve over the range 125-125 000 ng/mL was prepared in acetonitrile. For MMF, two 7-point internal standard curves, one over the range 5-2000 ng/mL and the other 1000-120 000 ng/mL of MMF, were prepared in dimethyl sulfoxide (DMSO):acetonitrile (1:1, v/v). Sample supernatants comprised similar proportions of HLM, buffer, solvent, and internal standard as present in the samples prior to analysis with LC-MS/MS.
| Assessment of DMF and MMF as inhibitors of CYP enzymes in vitro
The potential of DMF and MMF to inhibit CYP enzymes was investigated using EMA-and FDA-recommended substrates and inhibitors, 10, 11 with sample analysis by LC-MS/MS. Reactions were terminated after a 10-minute incubation period by removal of an aliquot into methanol containing the internal standard (appropriate volume based on CYP substrate).
Terminated samples were then prepared for LC-MS/MS analysis as described below.
| Analysis of CYP enzyme assay incubation samples
Analysis of CYP enzyme incubation samples was carried out as described in Table S3 . All samples underwent specific preparation using protocols that ensured the resulting supernatant comprised the same proportions of methanol, HLM and internal standard as present in the incubation samples prior to analysis by LC-MS/MS. Cryopreserved plated human hepatocytes in 24-well plates, isolated from one individual (identified with lot number EBS) were used (Table   S4 ). Following thawing, the supplemented medium was removed and replaced with 0.5 mL of fresh prewarmed supplemented medium con- Cell viability was assessed using the AQ ueous One Solution (Promega) colorimetric cell proliferation assay. The reagent contains
|
and an electron coupling reagent (phenazine ethosulfate; PES).
The MTS-PES mixture was thawed at ambient temperature. (Table S1 ).
| Assessment of MMF induction potential
The potential of MMF to increase messenger ribonucleic acid ( Table S4 ) in 24-well plates were used in this phase of the study.
Following thawing, the supplemented medium was removed and replaced with fresh pre-warmed supplemented medium containing the following components in the appropriate (triplicate) wells:
, and methanol, each at 0.5% of the final incubation volume.
Plates were incubated, and samples collected as described under "Assessment of MMF cytotoxicity." Plated hepatocytes were assessed for attachment and cell morphology by visual microscopic inspection. 
| Measurement of CYP mRNA levels
Samples were prepared after incubation by removing medium from the relevant wells and replacing with 500 μL RNAprotect (Qiagen, 
| Assessment of DMF and MMF as substrates and inhibitors of P-gp in vitro
| Test systems
Both human Caucasian colon adenocarcinoma (Caco-2) and trans- 
| Permeability assessment of DMF and MMF
The apparent cell permeability (permeability coefficient, P app ) for apical to basolateral (A-B) and basolateral to apical (B-A) transport of DMF and MMF was assessed in triplicate over a range of concentrations (DMF:
0.333-6.66 mmol/L; MMF: 0.0738-7.38 mmol/L) using the Caco-2 cells.
Plates were initially rinsed three times with CacoReady™ buffer and pre-incubated for 30 minutes at 37°C and 5% CO 2 . DMF and MMF were administered to apical or basolateral well compartments.
Triplicate samples from the corresponding solutions were also sampled as a measure of the time zero concentration. The transport experiment was established via reconstruction of the receiver and donor compartments into one plate following dosing.
Samples were taken from the donor compartment at 120 minutes and from the receiver compartment at 0 and 120 minutes. The permeability experiment was terminated after 120 minutes by separation of the receiver and donor compartments. Bidirectional transport of DMF and MMF was measured, as was bidirectional transport of the high and low permeability markers propranolol and atenolol.
Samples were prepared for analysis by LC-MS/MS as described in Table S1 (DMF and MMF) and Table S5 (atenolol and propranolol).
| P-gp substrate assessment
DMF and MMF were assessed as potential substrates of P-gp in the analyzed by LC-MS/MS as described in Table S1 . Bidirectional transport of the probe substrate [ 3 H]digoxin with and without verapamil was also assessed in triplicate after 120 minutes.
| P-gp inhibition assessment
DMF and MMF were assessed as potential inhibitors of P-gp in both Caco-2 and MDCKII-MDR1 and MDCKII-WT cells.
Monolayers were cultured and incubated in triplicate as described above.
[ Bidirectional transport of the high and low permeability markers propranolol and atenolol was also measured; these samples were analyzed by LC-MS/MS (Table S5) .
| RE SULTS
| Assessment of DMF and MMF as inhibitors of CYP enzymes in vitro
| Preliminary solubility experiment
Preliminary solubility experiments showed that DMF and MMF were soluble up to 666 and 750 µmol/L, respectively. Calculated recoveries of DMF before and after centrifugation were generally low, most likely a consequence of its instability in the presence of HLM (see "Preliminary metabolic stability experiment").
Concentrations within 20% of nominal were achieved upon spiking MMF into solutions of HLM at 0.025 and 0.3 mg/mL. MMF concentration did not change upon centrifugation (mean recovery >92.2%).
| Preliminary metabolic stability experiment
The assessment of metabolic stability indicated that DMF was unlikely to be stable under the incubation conditions (target concentrations were achieved with 666 μmol/L DMF in 0.1 mg/mL HLM only).
In contrast, 750 μmol/L MMF was stable in the preliminary investigations. To ensure that inhibition could be ascribed to DMF in the CYP assays, DMF concentrations were measured over the incubation period under experimental conditions (Table S6) . Concentration checks performed within the assays confirmed the presence of DMF (albeit at much reduced concentrations) at the end of the incubation period.
| Inhibitory potential of DMF and MMF for CYP enzymes
DMF and MMF were investigated for their potential as both a direct competitive inhibitor and time-dependent inhibitor of selected CYP enzymes. This was achieved by assessing the potency of inhibition following no pre-incubation (0 minute) and a pre-incubation of Positive control inhibitor assays showed inhibition of at least 95.0% and at least 70.6% with ketoconazole and azamulin, respectively, in the presence of both testosterone and midazolam (data not shown). These data confirmed that the experimental system was capable of monitoring inhibitory activity.
MMF at concentrations up to 750 μmol/L did not inhibit any of the CYP enzymes investigated (maximum reversible inhibition
was 30% of CYP2D6 and maximum time-dependent inhibition was 28% of CYP2C19) (Figure 1 ). In all scenarios tested, IC 50 values could not be calculated as insufficient inhibition (<50%) was reported. Thus, by inference, IC 50 values were >750 μmol/L.
Positive control inhibitor data confirmed that the experimental system was capable of monitoring inhibitory activity (data not shown).
Together, these data indicate that DMF and MMF are not reversible or time-dependent inhibitors of any of the CYP enzymes examined.
| Cytotoxic potential of MMF and its ability to induce CYP enzymes in cultured human hepatocytes
| MMF solubility in incubation medium
On spiking the prepared MMF solution into warm, supplemented
Williams' Medium E, no precipitation or insoluble material was observed. Post-centrifugation recoveries of MMF up to 750 μmol/L were ≥86.5% and therefore no solubility issues were noted. 
| Assessment of the cytotoxic potential of MMF
| Permeability of DMF and MMF across Caco-2 cell monolayers
The permeability of DMF was concentration-dependent at all of the timepoints investigated. Moderate-to-high P app was seen in both supporting the finding that DMF is not a substrate of P-gp.
Similarly, the net efflux ratio reported for MMF (at 120 minutes)
was <2 x 10 -6 cm/s at all concentrations investigated, indicating that MMF does not act as a substrate of P-gp.
In both DMF and MMF experiments, the probe substrate
digoxin showed a net efflux ratio of >16.6, which was reduced in the presence of verapamil. These data confirmed that the test systems were able to assess P-gp substrate interactions.
| DMF and MMF as potential P-gp inhibitors
Caco-2 cell line
Experiments in the Caco-2 cell line in the absence of DMF and MMF demonstrated notable differences in P app of [ ( Table 2 ).
In the presence of the reference inhibitor, verapamil, the [ 3 H]digoxin efflux ratio was reduced by ≥80% versus [ 3 H]digoxin alone at 120 minutes. These data indicate that the experimental test system was able to assess P-gp inhibitory interactions.
MDCKII cell line
DMF and MMF inhibitory potential was also assessed in the MDCKII cell line. [ 3 H]Digoxin net efflux ratios decreased with increasing concentrations of DMF, which suggested inhibition by DMF of P-gp (Table 2) , with an estimated IC 50 value of 0.9 mmol/L ( Figure 6B ).
At MMF concentrations of 0.0738, 0.246, 0.738, and 7.38 mmol/L, the net efflux ratio of [ 3 H]digoxin was effectively unchanged (Table 2 ). These data demonstrate that MMF was not an inhibitor of P-gp at concentrations up to 7.38 mmol/L.
In the presence of verapamil, the efflux ratios of [ 3 H]digoxin were reduced by a minimum of 61% in MDCKII cells, indicating that the experimental test system was able to assess inhibitory interactions.
| Caco-2 and MDCKII cell layer integrity
TEER results demonstrated that the electrical resistance in all wells used was >1000 Ω.cm 2 per well for Caco-2 cells and >83 Ω.cm 2 per
well for MDCKII cells. This indicated the presence of intact monolayers and confirmed that the Caco-2 and MDCKII cell monolayers used were suitable for use in drug transport studies with DMF and MMF.
Permeability marker compounds were assessed for permeability across the cell monolayers. For atenolol, all P app values met the acceptance criterion of <2 × 10 −6 cm/s, which indicated that atenolol behaved as a low permeability compound. For propranolol, all P app values were >10 × 10 -6 cm/s, thus meeting the acceptance criterion and indicating that propranolol behaved as a medium to high permeability compound. 
F I G U R E 2
| D ISCUSS I ON
Although DMF has been in use for some decades as part of a mixture of FAE, the introduction of DMF as a monotherapy and its demonstration of noninferiority to the long-established FAE mixture 3 have generated renewed interest in this mode of treatment. 14, 15 The work presented here was prompted by regulatory requirements. For transparency, these data should be made publicly available because the relevant data points on the potential effect of DMF and its major metabolite on CYP enzymes (with accompanying implications for DDIs) and the kinetics of drug transport [10] [11] [12] 16, 17 are not currently included in available summaries of product characteristics. Although not a substrate for P-gp (see later), DMF is likely to be a weak inhibitor of P-gp, because efflux and net efflux ratios of is noted also that atenolol and propranolol were found to be suitable and predictable controls for the study of drug permeability and active transport in the Caco-2 and MDCKII cell monolayers. Efflux ratio = (P app (B-A)/P app (A-B) ). b Net efflux ratio = efflux ratio in transfected cells/efflux ratio in wild-type cells.
TA B L E 2 Assessment of DMF and MMF as potential inhibitors of P-gp following a 120-minute incubation
In conclusion, this study demonstrates that neither DMF nor MMF is a direct inhibitor of any of the CYP enzymes investigated, nor are they likely to induce CYP at clinically relevant concentrations. They are therefore not predicted to alter the disposition of other compounds metabolized by CYP enzymes. DMF is not a substrate for P-gp within the therapeutic concentration range but may be a weak inhibitor at supratherapeutic concentrations unlikely to have any clinical relevance given the high IC 50 for DMF (in the millimolar range). MMF was neither a substrate nor an inhibitor of P-gp. DMF is expected to demonstrate moderate-to-high absorption across the gastrointestinal tract, while MMF is expected to demonstrate low permeability. Results show no evidence for MMF interaction with CYP enzymes and the clinically important P-gp transporter.
Therefore, no interactions are expected with medicinal products metabolized or transported by these systems.
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